Demonstrating the Robustness and Reproducibility of a γδ T Cell Manufacturing Workflow
IN8bio partnered with iRepertoire to characterize a novel γδ T cell therapy for glioblastoma. Using RepSeq+ TCR profiling and ImmunoSight™ gene expression analysis, they demonstrated that the manufacturing process—not donor variability—drives the final therapeutic profile. The workflow consistently expanded Vγ9/Vδ2 clones and upregulated key activation and trafficking genes, confirming both the robustness of the process and the functional potency of the product.
Download the full case study to explore how iRepertoire’s multi-omic profiling can accelerate cell therapy development and quality control.
